Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2017 06:00 ET | Source: BeiGene, LTD.

BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer

BEIJING, China and CAMBRIDGE, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
September 08, 2017 06:00 ET | Source: BeiGene, LTD.

BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress

CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
June 05, 2017 09:00 ET | Source: BeiGene, LTD.

BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for...
April 21, 2017 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for...
December 21, 2016 16:15 ET | Source: BeiGene, LTD.

BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290

BEIJING, Dec. 21, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of...